ValiRx plc
VAL.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | -£0 | £0 | £0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 418.5% | – | – | – |
| Gross Profit | -£0 | -£0 | -£0 | -£0 |
| % Margin | -436.4% | -2,562.9% | – | – |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -3,741.2% | -21,295.2% | – | – |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -3,848.7% | -21,226.1% | – | – |
| EPS Diluted | -0.015 | -0.02 | -0.031 | -0.024 |
| % Growth | 27.9% | 35.4% | -30.7% | – |
| Operating Cash Flow | -£0 | -£0 | -£0 | -£0 |
| Capital Expenditures | -£0 | -£0 | £0 | £0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |